KRAS and neoplasm: HOXC10 accelerates cancer progression by activating both MAPK47 and PI3K/AKT pathways,48 which are the main downstream pathways of KRAS.49 Study have shown that BET bromodomain epigenetic signaling interferes with the bone-associated tumor vicious cycle.50 More importantly, HOXC10 expression inversely correlated with PRC2- BET bromodomain epigenetic signaling activity.51 These findings support a link between HOXC10 dysregulation and KRAS-mutant lung cancer with bone metastasis.